pharma · Prostate Cancer · Hot Flush
Astellas Pharma
Astellas Pharma GmbH
Astellas Pharma clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 22
- Drugs
- 52
- Patents
- 25
Astellas Pharma projects
8 ClinicalTrials.gov programs sponsored by Astellas Pharma.
Astellas Pharma has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
1570-CL-0101
Astellas Pharma GmbH
Advanced Solid Tumors
1 trial -
2215-CL-0603
Astellas Pharma GmbH
FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
1 trial -
5541-CL-0201
Astellas Pharma GmbH
Prostate Cancer
1 trial -
8951-CL-0103
Astellas Pharma GmbH
Advanced cancer of the stomach or the gastroesophageal junction
1 trial -
8951-CL-5201
Astellas Pharma GmbH
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.
1 trial -
9785-CL-0123
Astellas Pharma GmbH
Prostate Cancer
1 trial -
ASP2957
Astellas Pharma GmbH
X-linked myotubular myopathy
1 trial -
PMR-EC-1206
Astellas Pharma GmbH
Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection
1 trial
Frequently asked questions
How many clinical projects does Astellas Pharma have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.